How we turn high impact innovations into excellent patient care

Through our Clinical Academic Groups and Institutes, we bring experts in their fields together so that we can offer patients and service users the very best care. We round up some top examples of our translational research.

At our 2019 Annual Conference, we held a series of 7x7 impact talks, exploring how we have translated research from the laboratory bench to a patients’ bedside.

Prof Sir Robert Lechler: improving transplantation tolerance

Prof Sir Robert Lechler, Executive Director of King's Health Partners, explains regulatory cells, their properties and how his work has helped identify a lower-risk transplant method that improves a patient’s tolerance to a transplant.

To do the research that I’ve described is totally dependent on bringing scientists and clinicians and patients together so that the work can be done.


Prof Sally Barrington: using PET to treat Hodgkin lymphoma

Prof Sally Barrington, Professor of PET imaging at King's College London, explains an innovative imaging technique that can monitor the effects of treatment for Hodgkin lymphoma earlier and more effectively than previous techniques. This helps provide patients with more personalised treatment.

Working in an Academic Health Sciences Centre…enables me as a person who delivers a clinical service and is working with patients within the NHS on the frontline to also carry out research.


Prof Sir John Strang: naloxone without the needle

Prof Sir John Strang, Leader of King's Health Partners Addictions Clinical Academic Group, discusses the developments of take-home naloxone as a concept that can make the life-saving drug more accessible to addicts and their families who need it.

The concept of the Clinical Academic Group gave us the ability to integrate the academic interest in the addiction field with hands-on clinical management of people with addiction problems.


Prof Reza Razavi: advances in MRI-guided electrophysiology

Prof Reza Razavi, Director of Research at King's Health Partners, explains how his cross-partner team are developing a curative treatment for ventricular fibrillation, the main cause of sudden cardiac death in the UK. This treatment has the potential to take the current cure rate for ventricular fibrillation from 50% to the high 90s.

We have the colleagues in the university with expertise in the technology and engineering and we have the colleagues in the hospital with expertise in the clinical problems.


Prof Lucy Chappell: improving antenatal care

Prof Lucy Chappell, National Institute for Health Research Professor in Obstetrics at King’s College London and Honorary Consultant Obstetrician at Guy’s and St Thomas’ NHS Foundation Trust, discusses the development of a new diagnostic test for pre-eclampsia, shown to half the time to reach a diagnosis and reduce maternal complications.

King’s Health Partners provides an ideal environment in which to undertake this sort of translational research and it’s been incredibly supportive at all stages of that pipeline.


Prof Phillip McGuire: cannabis and psychosis

Prof Phillip McGuire, Academic Director and joint Leader of the Psychosis Clinical Academic Group, explores the potential of cannabidiol as new medicine in mental health that could represent a new class of treatment for certain conditions.

Working in King’s Health Partners…you get a fantastic synergy between the clinical and the academic activities.


Prof Andrew Tutt: first targeted treatment for hereditary cancer

Prof Andrew Tutt, Consultant Clinical Oncologist at Guy's and St Thomas' NHS Foundation Trust and Professor of Oncology, King’s College London, explains how by working alongside the Institute of Cancer Research, his team is developing the first targeted treatment for certain hereditary cancers.

It could not be done in one hospital alone and the relationship has allowed us to collaborate with…the national and international clinical trials community.


To learn more about how King’s Health Partners has led the way in breaking down barriers to combine basic and translational health research, visit our Impact page.